Philadelphia chromosome-positive (Ph+) ALL, characterized by the BCR-ABL1 fusion gene, has seen important advances through the incorporation of tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib, which are now standard components of therapy, as recommended by the NCCN [66,67,68]. Here, ABL1 is linked to acute lymphoblastic leukemia.